Navigation Links
In vitro infection and replication of hepatitis E virus in human hepatocytes
Date:4/2/2011

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus (HEV) in human hepatocytes.1

This study also verifies that HEV is a zoonosis (infectious disease that can be transmitted from animals to humans), which has been suggested for a long time.

HEV is a major cause of epidemic and acute sporadic hepatitis in many developing countries. It is also endemic in many industrialized countries, including the United States, European countries and Japan.

Four major genotypes (genotypes 1-4) of HEV have been identified in mammalian species. Genotype 3 and 4 HEVs are believed to undergo zoonotic transmission, with a reservoir in pigs and, possibly, a range of other mammals.


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Page: 1

Related biology news :

1. In vitro antibody production enables HIV infection detection in window period -- key to safer blood
2. Combined stem cell-gene therapy approach cures human genetic disease in vitro
3. Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infection
4. Latest hands-free electronic water faucets found to be hindrance, not help, in infection control
5. Nanomodified surfaces seal leg implants against infection
6. BUSM faculty author commentary on the global challenges of emerging viral infections
7. Researchers step closer to treatment of virulent hospital infection
8. Toxoplasmosis: The strain explains severity of infection
9. A more definitive test for a common sexually transmitted infection
10. Chemical compounds in trees can fight deadly staph infections in humans
11. Exposure to worm infection in the womb may protect against eczema, study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: